• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Trastuzumab deruxtecan is a treatment option for pre-treated HER2-low metastatic breast cancer

byKassandra McFarlaneandSze Wah Samuel Chan
June 13, 2022
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Median overall survival is longer for HER2-low breast cancer patients receiving trastuzumab deruxtecan compared with other chemotherapy treatment options.

2. Trastuzumab deruxtecan is associated with increased risk of interstitial lung disease and pneumonitis

Evidence Rating Level: 1 (Excellent)

Study Rundown: Treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer includes targeted treatment with trastuzumab, an anti-HER2 monoclonal antibody. An antibody-drug conjugate, trastuzumab deruxtecan, combines the monoclonal antibody with a topoisomerase I inhibitor and has been shown to be effective in highly expressed HER2 breast cancers. Because more than half of the HER2-negative breast cancers do express some amount of HER2, there is a possible therapeutic effect of this treatment in this heterogeneous group of patients. This study aimed to determine the outcome on progression-free survival (PFS), overall survival (OS), and safety of trastuzumab deruxtecan as compared with other standard chemotherapy treatment options as selected by a physician in patients with HER2-low metastatic breast cancer. The median PFS for all patients receiving trastuzumab deruxtecan was 9.9 months as compared to 5.1 months for patients on other chemotherapy. The median OS for all patients on trastuzumab deruxtecan was 23.4 months compared to 16.8 months in those receiving other chemotherapy. The majority of patients in the trastuzumab deruxtecan and the physician-chosen chemotherapy group experienced adverse effects (AEs) and roughly a quarter of AEs were serious. The most common drug-related AEs in the trastuzumab group were nausea, fatigue, and alopecia which occurred more frequently than in the physician-chosen chemotherapy group. Each group had AEs that were associated with death (14 in the trastuzumab group and 5 in the chemotherapy group), but there were no drug-related deaths in the chemotherapy group, while there were 3 drug-related deaths in the trastuzumab group. Limitations to this study include the applicability of this treatment to the specific groups that were ineligible to join the trial, for example, those with history of glucocorticoid treatment for noninfectious interstitial lung disease or who were suspected of having interstitial lung disease. Overall, treatment with trastuzumab deruxtecan will change practice as it defines a new category of HER2 expressing breast cancers that would benefit from this treatment over standard chemotherapy.

Click to read the study in The New England Journal of Medicine

Relevant Reading: The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy

In-Depth [randomized controlled trial]: This open-label, two group, phase 3 study enrolled a total of 557 patients with HER2-low metastatic breast cancer who were randomly assigned in a 2:1 ratio to receive either trastuzumab deruxtecan (n = 373) or another chemotherapy treatment option (n = 184). For all patients receiving trastuzumab deruxtecan the median PFS was 9.9 months (95% CI, 9.0 to 11.3 months) versus 5.1 months (95% CI, 4.2 to 6.8 months) for patients on other chemotherapy (HR, 0.50; 95% CI, 0.40 to 0.63). For all patients on trastuzumab deruxtecan the median OS was 23.4 months (95% CI, 20.0 to 24.8 months) versus 16.8 months (95% CI, 14.5 to 20.0 months) in the group receiving other chemotherapy treatment (HR, 0.64; 95% CI, 0.49 to 0.84). 99.5% of patients receiving trastuzumab deruxtecan and 98.3% of patients receiving other chemotherapy experienced AEs; the most common AEs were nausea (73% vs. 23.8%), fatigue (47.7% vs. 42.4%), and alopecia (37.7% vs. 32.6%). 12% of patients developed treatment related interstitial lung disease/pneumonitis.14 patients in the trastuzumab group had AEs associated with death, while 5 did in the other chemotherapy group.

RELATED REPORTS

Trastuzumab deruxtecan associated with lower risk of metastatic breast cancer progression

Trastuzumab deruxtecan superior to trastuzumab emtansine in patients with metastatic HER2 breast cancer

#VisualAbstract: Pertuzumab plus trastuzumab significantly improves survival in metastatic breast cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: HER2lowmetastatic breast cancertrastuzumab deruxtecan
Previous Post

Neoadjuvant dostarlimab is a promising treatment option in locally advanced dMMR rectal cancer

Next Post

The EAST-AFNET 4 trial: Early rhythm control therapy for atrial fibrillation [Classics Series]

RelatedReports

Preoperative bilateral breast imaging may reduce contralateral cancer recurrence
Chronic Disease

Trastuzumab deruxtecan associated with lower risk of metastatic breast cancer progression

March 29, 2022
Oncology

Trastuzumab deruxtecan superior to trastuzumab emtansine in patients with metastatic HER2 breast cancer

March 28, 2022
#VisualAbstract: Immunocompromised individuals may be at an increased risk of metastses with cutaneous squamous cell carcinomas
StudyGraphics

#VisualAbstract: Pertuzumab plus trastuzumab significantly improves survival in metastatic breast cancer

March 23, 2022
Endocrinology

Ribociclib plus letrozole provides greater overall survival benefit advanced breast cancer

March 17, 2022
Next Post
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

The EAST-AFNET 4 trial: Early rhythm control therapy for atrial fibrillation [Classics Series]

Forearm parathyroid reimplantation may be effective in preventing hypoparathyroidism

Primary hyperparathyroidism associated with an increased risk of fractures and cardiovascular events

Being overweight and obese associated with increased incidence of chronic kidney disease

Uric acid-lowering therapy not associated with improved kidney function

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Tirzepatide Once Weekly for the Treatment of Obesity
  • Wellness Check: Sleep
  • #VisualAbstract: Intravenous vitamin C increases mortality and organ dysfunction in sepsis patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.